Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Relenza Use In U.K. For 2000 Season Will Await Four Ongoing Glaxo Trials

Executive Summary

A recommendation in favor of prescribing Glaxo Wellcome's influenza therapy Relenza on the U.K.' s National Health Service for the 2000-20001 flu season will await the results of four ongoing trials, according to a report issued Oct. 8 by the National Institute for Clinical Excellence.

You may also be interested in...



Relenza Prophylaxis Indication Withdrawn In EU; Pediatric Use Cleared In U.S.

Glaxo Wellcome's influenza medication Relenza for prevention of flu was withdrawn from the EU mutual recognition process so the company could resubmit the application with more data in elderly and high-risk patients, Glaxo said.

Relenza Prophylaxis Indication Withdrawn In EU; Pediatric Use Cleared In U.S.

Glaxo Wellcome's influenza medication Relenza for prevention of flu was withdrawn from the EU mutual recognition process so the company could resubmit the application with more data in elderly and high-risk patients, Glaxo said.

Roche Withdraws Tamiflu European Application; Will Submit More Flu B Data

Roche will submit additional Tamiflu data supporting the drug's efficacy against influenza B after withdrawing its European application for the neauraminidase inhibitor.

Related Content

UsernamePublicRestriction

Register

PS034987

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel